Jane Street
IMUX icon

Jane Street’s Immunic IMUX Stock Holding History

Jane Street’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,510
Closed -$16.8K – 12307
2026
Q1 		$16.8K Buy
+1,510
New +$13.5K ﹤0.01% 11224
2023
Q1 		– Sell
-5,190
Closed -$72.7K – 9440
2022
Q4 		$72.7K Buy
+5,190
New +$142K ﹤0.01% 8245

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Jane Street's IMUX Position: Q2 2026 in Review

Jane Street increased its Immunic (IMUX) stake by 36% in Q2 2026, buying an estimated $293K and bringing the position to 89,687 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #5860.

Jane Street first reported a position in IMUX in Q2 2014 and has held it in 24 quarters since. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • Jane Street held 89,687 shares of Immunic worth $1.38M as of Q2 2026.
  • Jane Street bought 23,772 Immunic shares in Q2 2026, an estimated $293K.
  • Immunic made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #5860 holding.
  • Jane Street first reported a position in Immunic in Q2 2014 and has held it in 24 quarters since.
  • 55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.